Acorda Therapeutics (NASDAQ:ACOR) Earns Buy Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note released on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Stock Up 8.8 % Shares of NASDAQ ACOR opened at $14.80 on Thursday. Acorda Therapeutics has a 12-month low of $8.98 and […]
More Stories
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...